Immutep in Collaboration, Supply Agreement With Merck KGaA
01 Giugno 2021 - 2:46PM
Dow Jones News
By Chris Wack
Immutep Limited is in a new collaboration and supply agreement
with Merck KGaA, Darmstadt, Germany, for a Phase I/IIa clinical
trial in patients with solid tumors.
The biotechnology company said the trial will evaluate the
feasibility, safety and efficacy of Immutep's lead product
candidate, eftilagimod alpha, or IMP321, when given in combination
with bintrafusp alfa, an investigational bifunctional fusion
protein immunotherapy being jointly developed by Merck KGaA and
GlaxoSmithKline.
Bintrafusp alfa aims to block two immunosuppressive pathways,
TGF-<BETA> and PD-L1, while efti activates antigen presenting
cells, via the LAG-3--MHC II pathway.
Immutep said the trial will be conducted by the Institute of
Clinical Cancer Research, at Krankenhaus Nordwest in Frankfurt,
Germany, as an investigator-initiated trial.
The study will be run as an amendment to the protocol of the
ongoing Phase I trial as the fifth arm.
The trial is planned to take place in 2 clinical sites in
Germany. Immutep is financially supporting the trial to be run by
IKF, and Merck KGaA is financially contributing to the
biomarker-related work. The first patient is expected to be
enrolled in mid-2021 and the trial is expected to deliver first
data in early 2022.
Immutep shares were up 10% to $5.56 in premarket trading.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
June 01, 2021 08:35 ET (12:35 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Grafico Azioni Gsk (LSE:GSK)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Gsk (LSE:GSK)
Storico
Da Apr 2023 a Apr 2024
